Elizabeth Zarate-Rowell
Psychiatry · Seal Beach, CANPI 1992830236
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $23,261 of the $26,620 with a category attached, or 87.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $8,852, 5.3 times the $1,686 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- plus $9K from 13 others
Across 857 payments — averaging $4473.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Teva Pharmaceuticals USA, Inc.$567K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$317K
- H. Lundbeck A S$309K
- Acadia Pharmaceuticals Inc$243K
- Boehringer Ingelheim$232K
- plus $1.1M from 20 others
What the payments were for
- Speaking & faculty fees$8753%
- Travel & lodging$2,1938%
- Food & beverage$23,26187%
- Education$2921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 101 | $3,730 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 114 | $3,501 |
| Alkermes, Inc. | 90 | $3,147 |
| Otsuka America Pharmaceutical, Inc. | 46 | $2,909 |
| Neurocrine Biosciences, Inc. | 39 | $2,314 |
| Sunovion Pharmaceuticals Inc. | 56 | $2,220 |
| AbbVie(2 entities) | 116 | $2,048 |
| Janssen Research & Development, LLC | 13 | $2,026 |
| Teva Pharmaceuticals USA, Inc. | 29 | $1,149 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $1,132 |
| Vanda Pharmaceuticals Inc. | 8 | $584 |
| E.r. Squibb & Sons, L.L.C. | 16 | $557 |
| Indivior Inc. | 14 | $396 |
| Axsome Therapeutics, Inc. | 6 | $379 |
| Janssen Scientific Affairs, LLC | 3 | $231 |
| Novo Nordisk | 2 | $132 |
| Harmony Biosciences LLC | 3 | $107 |
| Eisai Inc. | 1 | $35 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$3,905
- LYBALVI$2,870
- CAPLYTA$1,621
- ABILIFY MAINTENA$1,413
- INVEGA SUSTENNA$1,346
- INVEGA TRINZA$1,249
- ARISTADA INITIO$976
- REXULTI$957
- Fanapt$498
- ABILIFY ASIMTUFII$478
- UZEDY$477
- INGREZZA$401
- VRAYLAR$355
- COBENFY$253
- Auvelity$245
- Austedo XR$220
- Wegovy$121
- PERSERIS$120
- LONHALA MAGNAIR$115
- LATUDA$113
How this compares
$26,620 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 21 | $160,786 |
| Abilify MaintenaAripiprazole | 15 | $40,788 |
| CaplytaLumateperone Tosylate | 33 | $39,728 |
| Invega SustennaPaliperidone Palmitate | 11 | $34,730 |
| VraylarCariprazine Hcl | 20 | $27,674 |
| OzempicSemaglutide | 13 | $12,153 |
| Clozapine | 96 | $10,208 |
| Oxcarbazepine | 35 | $2,764 |
| Lurasidone Hcl | 31 | $2,313 |
| Gabapentin | 51 | $1,453 |
| Divalproex Sodium | 18 | $1,220 |
| Olanzapine | 34 | $1,050 |
| Propranolol Hcl | 39 | $560 |
| AmantadineAmantadine Hcl | 12 | $486 |
| Benztropine Mesylate | 21 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,149 | $160,78621 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $2,909 | $40,78815 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,501 | $39,72833 claims |
| Johnson & JohnsonInvega Sustenna | $3,730 | $34,73011 claims |
| AbbVieVraylar | $2,048 | $27,67420 claims |
| Novo NordiskOzempic | $132 | $12,15313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Seal Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.